D3.456 - BEAMER: A multidisciplinary model for disease-agnostic adherence integrating chronic rhinosinusitis: development and prospective study

Adherence is a key feature for successful treatment outcome. Nevertheless, lack of adherence is widespread, affecting any disease and leading to treatment failures, comorbidities, decreased quality of life and additional costs. 

The EU-funded project BEAMER "Behavioural and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe" generates a disease-agnostic, superordinated and overarching Minimum Viable Product (MVP) to predict individual adherence. Furthermore, it directly enables a transformation of the stakeholders’ engagement with patients to improve healthcare accessibility and sustainability. During modelling with modern statistical methods, the needs of all stakeholders (patients, HCPs, product development/commercialization) are respected in representative settings: immunology (in CRS as a “signature disease” 1512 patients were included), oncology, cardiology, neurology, endocrinology, rare disease. 

The BEAMER model enables stakeholders to identify 8 different groups of patient adherence through the application of a standardized questionnaire. Each subtype is connected to an advisory recommendation enabling direct interaction support. A prospective validation and practical testing of the model is performed in a clinical study including up to 500 patients with CRS with/without treatment of biologicals, allergic patients undergoing allergen immunotherapy, and patients suffering from angioedema. Preliminary disease-specific data will be presented. Additional outcome measurements include clinical features, symptom scoring, distress and quality of life measurements.  

The BEAMER model provides a disease-agnostic model to determine adherence. It also offers accompanying digital support to improve patient-stakeholder interaction.